Effects of Bazedoxifene/Conjugated Estrogens on the Endometrium and Bone: A Randomized Trial

Pinkerton, JoAnn V.; Harvey, Jennifer A.; Lindsay, Robert; Pan, Kaijie; Chines, Arkadi; Mirkin, Sebastián; Archer, David F.; Investigators, Smart

doi:10.1210/jc.2013-1707

Cited by 127 publications

(105 citation statements)

References 25 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…A new strategy for ER modulation, known as tissue selective estrogen complex (TSEC), combines estrogen therapy (conjugated equine estrogens) with bazedoxifene. Data from clinical trials indicate that this association leads to improvements of menopausal symptoms and bone mass, without causing adverse effects on the breast and uterus (116)(117)(118)(119)(120). However, the anti-fracture and cardiovascular effects of this association have not been adequately investigated yet.…”

Section: Selective Estrogen Receptor Modulatorsmentioning

confidence: 99%

Guidelines for the diagnosis, prevention and management of osteoporosis

et al. 2016

View full text Add to dashboard Cite

Osteoporosis poses a significant public health issue. National Societies have developed Guidelines for the diagnosis and treatment of this disorder with an effort of adapting specific tools for risk assessment on the peculiar characteristics of a given population. The Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS) has recently revised the previously published Guidelines on the diagnosis, riskassessment, prevention and management of primary and secondary osteoporosis. The guidelines were first drafted by a working group and then approved by the board of SIOMMMS. Subsequently they received also the endorsement of other major Scientific Societies that deal with bone metabolic disease. These recommendations are based on systematic reviews of the best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on leading experts' experience and opinion, and on good clinical practice. The osteoporosis prevention should be based on the elimination of specific risk factors. The use of drugs registered for the treatment of osteoporosis are recommended when the benefits overcome the risk, and this is the case only when the risk of fracture is rather high as measured with variables susceptible to pharmacological effect. DeFRA (FRAX® derived fracture risk assessment) is recognized as a useful tool for easily estimate the long-term fracture risk. Several secondary forms of osteoporosis require a specific diagnostic and therapeutic management

show abstract

Section: Selective Estrogen Receptor Modulatorsmentioning

confidence: 99%

Guidelines for the diagnosis, prevention and management of osteoporosis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Most clinicians use raloxifene for the management of osteoporosis in patients with contraindications to other antiresorptive agents or for the treatment of women desirous of breast cancer prevention in whom enhanced skeletal health would be an additional Clinical Therapeutics benefit. 58 Of note, the third-generation SERM bazedoxifene in combination with conjugated estrogens 59 was recently approved by the US Food and Drug Administration (FDA) for the prevention of postmenopausal osteoporosis.…”

Section: Estrogen/selective Estrogen Receptor Modulatorsmentioning

confidence: 99%

The Pathophysiology and Treatment of Osteoporosis

Drake¹,

Clarke²,

Lewiecki³

2015

Clinical Therapeutics

217

144

View full text Add to dashboard Cite

“…In one 12-month trial, the incidence of endometrial hyperplasia and bleeding with Duavive was similar to that observed with placebo and it was not associated with breast tenderness. 2 There is little clinical experience of Duavive in women aged over 65 years, it is not recommended for women with renal impairment and it is contraindicated in those with hepatic impairment. Other prescribing cautions and contraindications are similar to those of other HRT preparations.…”

Section: Propertiesmentioning

confidence: 99%